Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + rucaparib
- Development stage
- Phase 2
- Lead developer
- Clovis Oncology
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cisplatin + rucaparib is a combination therapy consisting of cisplatin, a platinum-based chemotherapy agent, and rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. This combination has been investigated primarily in clinical trials for triple-negative breast cancer (TNBC) patients who had residual disease after standard neoadjuvant chemotherapy. The rationale behind this combination is based on the hypothesis that TNBC has an exploitable DNA damage repair defect similar to that seen in patients with germline BRCA mutations, which might be targeted by both cisplatin and PARP inhibition.
02
Targets
DNAPARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on cisplatin + rucaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + rucaparib.